Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?

A. D. Struthers

Status and phase: Completed; Phase 4

Conditions: Left Ventricular Hypertrophy; Kidney Disease

Treatments: Drug: Placebo; Drug: Allopurinol

Study type: Interventional

Funder types: Other

Identifiers

NCT00688480

MK001

Details and patient eligibility

About

Cardiovascular related disease is the main cause of death in patients with kidney disease, and "oxidative stress" is thought to be a major contributor by promoting thickening of the heart muscle and stiffening of the arteries. Allopurinol, a drug used safely in the treatment of gout for many years, has been found to dramatically reduce "oxidative stress". It is therefore hoped that it also reduce the thickened heart muscle and stiffened arteries. If it did, it is likely to reduce the appallingly high cardiac death rate in this group of kidney disease patients.

Enrollment: 67 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• CKD stage 3
• Echo LVH

Exclusion criteria

• Known heart failure
• Patients already on Allopurinol
• Patients with gout
• Patients with hepatic disease
• Contraindications to MRI, including severe claustrophobia
• Current immunosuppressive therapy, chlorpropamide, theophylline, 6- mercaptopurine
• Malignancy or other life threatening disease
• Pregnancy or lactating women
• Patients unable to provide written consent

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

67 participants in 2 patient groups, including a placebo group

I

Placebo Comparator group

Description:

CKD Stage 3 (estimated GFR 30 - 60 ml/min/1.73m2), Echo LVH

Treatment:

Drug: Placebo

2

Active Comparator group

Treatment:

Drug: Allopurinol